Advicenne announces commercialization agreement with FrostPharma AB for Sibnayal™ in the Nordic region
04 Janvier 2022 - 1:00PM
Advicenne announces
commercialization
agreement with FrostPharma AB
for Sibnayal™
in the Nordic region
-
Advicenne will receive a transfer price and royalties for an amount
markedly higher than 50% of future sales of Sibnayal™
-
Sibnayal™ will be marketed to one-third of European patients by
three members of the exclusive ‘Your Pharma Partner’ network
Paris, France,
4 January 2022
– 7:00am (CET)
– Advicenne (Euronext: ADVIC) (or the "Company"),
a specialty pharmaceutical company dedicated to developing and
commercializing innovative treatments for those suffering from rare
renal diseases, is pleased to announce that it has signed an
exclusive distribution agreement with FrostPharma AB
(“FrostPharma”), a Swedish pharmaceutical company, for the
commercialization of Sibnayal™ in the Nordic region (Denmark,
Finland, Iceland, Norway, and Sweden).
The partnership with FrostPharma is the third
Advicenne has signed for Sibnayal™ in Europe, following the
recently signed similar collaborations with TwinPharma in Benelux,
and ExCEEd Orphan in Central and Eastern European Countries. The
three companies comprise the exclusive ‘Your Pharma Partner'
network, providing services and delivering innovative treatments to
patients in 25 European countries. With these three partners,
Sibnayal™ will be made available to about a third of European
patients.
Sibnayal™ is the first and only label-approved
drug for the treatment of Distal renal tubular acidosis (dRTA) in
adults, adolescents, and children aged one year and older. Earlier
this year, the European Commission granted marketing authorisation
to Sibnayal™ for the treatment of dRTA.
Under the terms of the agreement, FrostPharma
will receive exclusive marketing rights to Sibnayal™ for the
treatment of dRTA in its respective market. For its part, Advicenne
will receive a transfer price for the sale of its product and
royalties for an amount significantly higher than 50% of future
sales. As part from the agreement, FrostPharma is also managing the
Early Access Program running for Sibnayal™ in Sweden.
Didier Laurens, Chief Executive Officer
of Advicenne, commented:
“We are delighted to be partnering with FrostPharma, a leader in
the commercialization of a broad range of products across many
disease areas. This is Advicenne’s third partnership for the
commercialization of Sibnayal™ in just over a few weeks and is
testament of our Company’s momentum. We have found in FrostPharma a
partner that shares our same goal: delivering life-changing
treatments for patients in areas of huge unmet need and we are
looking forward to working together.”
Clas
Lindbergson, Head of
Business Development of
FrostPharma
stated: “We are
proud to be partnering with Advicenne for the delivery of Sibnayal™
to patients and improve the lives of those suffering from Distal
Renal Tubular Acidosis (dRTA). We look forward to working with them
and to be continuing to expand our product portfolio in areas of
high unmet need.”
About
Advicenne Advicenne (Euronext: ADVIC) is a specialty
pharmaceutical company founded in 2007, specializing in the
development of innovative treatments in Nephrology. Its lead
product SibnayalTM (ADV 7103) has received its Marketing Approval
for distal renal tubular acidosis in EU and the UK. ADV 7103 is
currently in late-stage development in cystinuria in Europe and in
dRTA and cystinuria in the US. Headquartered in Paris, Advicenne
has been listed on the Euronext Paris stock exchange since 2017 and
was cross-listed on the Euronext Brussels stock exchange in 2019.
For additional information see: https://advicenne.com/.
About
Frost Pharma ABFrostPharma AB is
an entrepreneurial Swedish pharmaceutical company specialized in
commercialization of products creating value. Since the start in
2017, FrostPharma has successfully commercialized a broad range of
products across multiple disease areas, covering all Nordic
countries and beyond. Key to success is the ability to match
specific patient- and healthcare needs with relevant products in
relation to our extensive in-house commercialization competence.
www.frostpharma.se
About Your Pharma Partner in
EuropeYour Pharma Partner in Europe is a joint
collaboration alliance between the independent pharmaceutical
companies TwinPharma (the
Netherlands), FrostPharma (Sweden)
and ExCEEd
Orphan (Central and Eastern Europe). One
single point of contact gives the opportunity to reach a combined
market of 180 million Europeans in 25 countries.
www.yourpharmapartner.eu
CONTACTS
AdvicenneDidier Laurens, CEO+33 (0)4 66 05 54
20Email: investors@advicenne.com |
Ulysse CommunicationMedia
relationsBruno Arabian+33 (0)6 87 88 47 26Email:
advicenne@ulysse-communication.com |
Consilium Strategic CommunicationsMary-Jane
Elliott, Ashley Tapp, Davide Salvi+44 (0)20 3709 5700Email:
advicenne@consilium-comms.com |
|
Forward-Looking Statements
This press release contains certain
forward-looking statements relating to the business of Advicenne,
which shall not be considered per se as historical facts. Such
statements include projections and estimates, and the hypotheses on
which these are based, as well as observations relating to
operations, ongoing projects, objectives, the development of
products and their future performance, and expectations regarding
financial results.
In some cases, forward-looking statements can be
identified by words such as "could," "should," "may," "expects,"
"anticipates," "believes," "intends," "estimates," "aims,"
"targets" or similar words. Although the management of Advicenne
believes that these forward-looking statements are reasonably made,
investors should be aware that they are subject to a number of
known and unknown risks and uncertainties and other factors that
may cause actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by these forward-looking
statements. In particular, the expectations of Advicenne could be
affected by, among other things, uncertainties involved in the
placing on the market and commercialization of Advicenne products
or any other risks and uncertainties developed or identified in any
public documents filed by Advicenne with the French Financial
Markets Authority (Autorité des marchés financiers (AMF)),
including those listed in Chapter 3, “Risk Factors,” of its
universal registration document, filed with the latter on December
6, 2021. Notwithstanding the compliance with article 223-1 of the
General Regulation of the AMF (the information disclosed must be
“accurate, precise and fairly presented”), Advicenne disclaims any
intention or obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Please click HERE to see press release in
French.